<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03312751</url>
  </required_header>
  <id_info>
    <org_study_id>NI-0501-09</org_study_id>
    <nct_id>NCT03312751</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis</brief_title>
  <official_title>An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess Its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients With Primary Hemophagocytic Lymphohistiocytosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovImmune SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NovImmune SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to expand the knowledge on the efficacy and safety of emapalumab
      (previously known as NI-0501) as a treatment for primary haemophagocytic lymphohistiocytosis
      (HLH) patients, with special focus on long-term outcome and quality of life assessments.
      Emapalumab can be administered as the first-line therapy, to patients not previously treated
      with the current standard of care, or can be given to patients who have either failed or were
      unable to tolerate the available standard of care.

      Emapalumab is to be administered until the start of conditioning, with an anticipated
      duration ranging from a minimum of 4 weeks to approximately 12 weeks and not exceeding 6
      months.

      After treatment completion, patients will continue in the study for long-term follow-up until
      1 year after either HSCT or last emapalumab infusion (if HSCT is not performed).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2019</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response at Week 8 or End of Treatment (if earlier)</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>Achievement of either Complete or Partial Response or HLH Improvement, at Week 8 or EOT (whichever occurs earlier)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Including survival to HSCT and post-HSCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients proceeding to HSCT</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PedsQL Score</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Assessment of the quality of life using the PedsQL &quot;Pediatric Quality of Life Inventory&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, severity, causality and outcomes of AEs (serious and non-serious)</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Incidence of circulating antibodies against emapalumab</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall Response at start of conditioning</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Achievement of either Complete or Partial Response or HLH Improvement, at start of conditioning</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum concentrations of emapalumab</measure>
    <time_frame>Up to 18 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacodynamic parameters</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Levels of total IFNγ, markers of its neutralization (CXCL9 and CXCL10) and other relevant disease biomarkers e.g. sCD25</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Primary Hemophagocytic Hymphohistiocytosis</condition>
  <arm_group>
    <arm_group_label>Emapalumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emapalumab</intervention_name>
    <description>Emapalumab will be administered by intravenous infusion, twice weekly.</description>
    <arm_group_label>Emapalumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary HLH patients with active disease.

          -  Treatment naïve patients or patients having already received HLH conventional therapy,
             but having failed or unable to tolerate current standard of care.

          -  Informed consent signed by the patient or by the patient's legally authorized
             representative.

          -  Guidance on contrqaception

        Exclusion Criteria:

          -  Diagnosis of secondary HLH consequent to a proven rheumatic, metabolic or neoplastic
             disease.

          -  Active Mycobacteria, Histoplasma Capsulatum, Shigella, Salmonella, Campylobacter or
             Leishmania infections.

          -  Evidence of latent tuberculosis.

          -  Presence of malignancy.

          -  Concomitant disease or malformation severely affecting cardiovascular, pulmonary,
             central nervous system (CNS), liver, or renal function, that in the opinion of the
             Investigator may significantly affect the likelihood to respond to treatment and/or
             the assessment of emapalumab safety and/or efficacy

          -  History of hypersensitivity or allergy to any component of the study regimen

          -  Receipt of a BCG vaccine within 12 weeks prior to Screening

          -  Receipt of a live or attenuated live (other than BCG) vaccine within 6 weeks prior to
             Screening

          -  Pregnant or lactating female patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carl Johan Treutiger, MD</last_name>
    <phone>+46(0)8 697 20 00</phone>
    <email>CarlJohan.Treutiger@sobi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix Children Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Henry, MD</last_name>
      <phone>602-933-0188</phone>
      <email>mhenry@phoenixchildrens.com</email>
    </contact>
    <investigator>
      <last_name>Michael Henry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Jeng, MD</last_name>
      <phone>650-736-1177</phone>
      <email>mjeng@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Jeng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045-7106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Timothy Garrington, MD</last_name>
      <phone>720-777-6740</phone>
      <email>timothy.garrington@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Timothy Garrington, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfred I. duPont Hospital for Children - Nemours Center for Cancer and Blood Disorders - Division of Pediatric Hematology Oncology</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Powell, MD</last_name>
      <phone>302-651-5505</phone>
      <email>Jonathan.Powell@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Jonathan Powell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shanmuganathan Chandrakasan, MD</last_name>
      <phone>404-727-8877</phone>
      <email>shanmuganathan.chandrakasan@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Shanmuganathan Chandrakasan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute (DFCI)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara A Degar, MD</last_name>
      <phone>617-632-5186</phone>
      <email>barbara_degar@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Barbara Degar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Helen Devos Children's Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torrey Horness</last_name>
      <phone>616-267-6332</phone>
      <email>torrey.horness@helendevoschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Beth Kurt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Jordan, MD</last_name>
      <phone>513-636-9461</phone>
      <email>Michael.Jordan@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Michael Jordan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linna Zhang</last_name>
      <phone>832-824-4592</phone>
      <email>lxzhang@txch.org</email>
    </contact>
    <investigator>
      <last_name>Carl Allen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Miracle Network Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicholas S Whipple, MD</last_name>
      <phone>801-662-4700</phone>
      <email>nicholas.whipple@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Nicolas S Whipple, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Baker, MD</last_name>
      <phone>206-667-5594</phone>
      <email>ksbaker@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Scott Baker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Ste-Justine Research Center</name>
      <address>
        <city>Montréal</city>
        <zip>QC H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elie Haddad, MD</last_name>
      <phone>514 345-4931</phone>
      <phone_ext>4713</phone_ext>
      <email>elie.haddad@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>Elie Haddad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <zip>ON M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ahmed Naqvi, MD</last_name>
    </contact>
    <contact_backup>
      <phone>+1 416.813.3297</phone>
      <email>Ahmed.naqvi@sickkids.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Ahmed Naqvi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Beier, MD</last_name>
      <phone>+49 201 723 85190</phone>
      <email>Rita.Beier@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Rita Beier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center- University of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Ehl, MD</last_name>
      <phone>+49 (0) 761-270-77300</phone>
      <email>stephan.ehl@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Stephan Ehl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai Lehmberg, MD</last_name>
      <phone>+49 (0) 152-228-16726</phone>
      <email>k.lehmberg@uke.de</email>
    </contact>
    <investigator>
      <last_name>Kai Lehmberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Concetta Micalizzi, MD</last_name>
    </contact>
    <contact_backup>
      <phone>+39 010 5636.3572</phone>
      <email>concettamicalizzi@gaslini.org</email>
    </contact_backup>
    <investigator>
      <last_name>Concetta Micalizzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione MBBM, Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmelo Rizzari, MD</last_name>
      <phone>+39 039 233 3513</phone>
      <email>c.rizzari@asst-monza.it</email>
    </contact>
    <investigator>
      <last_name>Carmelo Rizzari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesu</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Locatelli, MD</last_name>
      <phone>+39 06 68592678</phone>
      <email>franco.locatelli@opbg.net</email>
    </contact>
    <investigator>
      <last_name>Franco Locatelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale della Donna e del Bambino</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Cesaro, MD</last_name>
    </contact>
    <contact_backup>
      <phone>+39 045 8127874</phone>
      <email>simone.cesaro@aovr.veneto.it</email>
    </contact_backup>
    <investigator>
      <last_name>Simone Cesaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Luis Dapena, MD</last_name>
    </contact>
    <contact_backup>
      <phone>+34 934 89 30 00</phone>
      <email>jldapena@vhebron.es</email>
    </contact_backup>
    <investigator>
      <last_name>Jose Luis Dapena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Niño Jesús</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Sevilla, MD</last_name>
    </contact>
    <contact_backup>
      <phone>+34 915035938</phone>
      <email>julian.sevilla@salud.madrid.org</email>
    </contact_backup>
    <investigator>
      <last_name>Julian Sevilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Zurich</name>
      <address>
        <city>Zürich</city>
        <zip>CH-8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana Pachlopnik Schmid, MD</last_name>
    </contact>
    <contact_backup>
      <phone>+41 44 266 32 66</phone>
      <email>Jana.Pachlopnik@kispi.uzh.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Jana Pachlopnik Schmid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds Children Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS13EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beki James, MD</last_name>
      <phone>+44113 392 8776</phone>
      <email>beki.james@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Beki James, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anupama Rao, MD</last_name>
      <phone>+44 2074059200</phone>
      <phone_ext>8190</phone_ext>
      <email>anupama.rao@gosh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Anupama Rao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Wynn, MD</last_name>
      <phone>+44 1617018417</phone>
      <email>robert.wynn@cmft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Robert Wynn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 5, 2017</study_first_submitted>
  <study_first_submitted_qc>October 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2017</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interferon-gamma</keyword>
  <keyword>NI-0501</keyword>
  <keyword>primary HLH</keyword>
  <keyword>emapalumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

